Last updated: April 23, 2026
What is AU2010212371 and what does it cover?
AU2010212371 is an Australian patent application (published as AU2010212371) in the drug space. The record is identified by an Australian application number and is relevant to Australian claim coverage only to the extent it enters and maintains effect in Australia.
Scope at a high level (what the patent is about):
- Intended claim territory: pharmaceutical compositions and/or uses tied to a specific drug substance and its administration in humans.
- Claim focus (typical for this application class): active ingredient, pharmaceutical formulation parameters, dosing regimen, and/or therapeutic use claims.
Core deliverable for claim-scope analysis:
- To assess scope and patent-landscape position, the analysis depends on the exact claim set (independent claims and dependent claim fallbacks) and the specification’s definitions (e.g., “pharmaceutically acceptable,” “effective amount,” “treating” terms, and any Markush boundaries).
Result: The provided input does not include the patent text (claims/specification), bibliographic family details, priority data, or claim-set excerpts required to produce a complete, accurate, claim-by-claim scope assessment for AU2010212371.
No complete claim analysis, scope charting, or landscape mapping can be produced from the single identifier alone without the actual published documents (claims text, description, and prosecution outcomes) and family links.
What are the independent claims and what is their enforceable scope?
A complete scope analysis requires:
- The verbatim independent claim wording (claim 1 and other independent claims, if multiple)
- The defined terms used in those claims
- The dependent claims that narrow the independent claim (e.g., specific dose ranges, formulation types, patient subgroups, combination partners)
Result: The claims for AU2010212371 are not included in the input. Without the claim text, any attempt to enumerate “what it claims” would risk factual error.
How broad are the claims: substance, formulation, method, or use?
A robust breadth assessment in Australia requires mapping each claim category:
- Product claims (composition of matter)
- Formulation claims (excipients, dosage forms, release profiles)
- Method-of-treatment claims (use of the drug to treat a disease)
- Use claims (therapeutic use statements framed as Swiss-type or EPC-style)
Result: Without the claim text, the breadth cannot be reliably classified (e.g., whether it is a composition claim vs a use claim).
What claim limitations typically drive infringement or non-infringement?
Claim construction in Australian practice turns on:
- Substance identity (active agent, salt form, stereochemistry)
- Quantity boundaries (mg per dose, concentration ranges, “effective amount” language)
- Formulation parameters (dosage form, excipients, release characteristics)
- Method steps (administration route, timing, duration)
- Indication language (disease definition, response criteria)
- Combination limitations (co-administered agents specified or implied by Markush language)
Result: The limitations for AU2010212371 depend on the actual claim language and defined terms, which are not provided.
What does this do to the patent landscape in Australia?
A correct landscape analysis must be anchored to:
- Patent family membership (priority filing, related jurisdictions)
- Other Australian filings in the family (if any)
- Relevant earlier rights (opposition/implied novelty blockers or earlier patents on the same active)
- Relevant later filings (grants that potentially overlap with the claimed formulation/dosing)
- Exclusivity status in Australia (including any linkage to ARTG/TGA data exclusivity if relevant)
Result: No family data, publication link, or related Australian grant/application list is included, so a landscape map for AU2010212371 cannot be completed accurately.
What are the key competitor and freedom-to-operate pressure points?
Freedom-to-operate pressure points for drug patents in Australia typically include:
- Earlier patents covering the active ingredient (composition-of-matter)
- Later “second-generation” patents covering formulations (e.g., extended-release, specific salts)
- Method-of-use patents tied to narrower indications or dosing regimens
- Parallel combinations (same active paired with other agents)
- Regulatory dossiers that trigger stacking or separation of IP protection
Result: Without AU2010212371’s claim set and family status, the likely overlap set cannot be identified.
How to interpret AU2010212371 within Australian practice (scope, validity, and enforceability)
An Australia-focused claims and landscape assessment must consider:
- Novelty and inventive step against prior art dates (priority and filing dates)
- Sufficiency of disclosure for claimed embodiments
- Clarity (support for claim boundaries)
- Patent term and maintenance (and whether the application proceeded to grant in Australia)
Result: These require the publication details and prosecution/grant status. None are included.
Status checks that materially change the landscape
A landscape conclusion depends on whether AU2010212371 is:
- Granted in Australia (and whether claims survived amendment)
- Lapsed, abandoned, or withdrawn
- Subject to opposition proceedings (if any)
- Part of a consolidated family with granted continuations
Result: No grant status information is included.
Tables: what cannot be filled without the document text
Because the input lacks the claims/specification, the following required tables cannot be completed accurately:
| Claim scope matrix (required): |
Claim No. |
Claim Type |
Core Element(s) |
Key Limitations |
Likely Infringement Trigger |
Likely Non-infringement Hook |
| 1 |
product/use/method |
(missing) |
(missing) |
(missing) |
(missing) |
| 2..n |
dependent |
(missing) |
(missing) |
(missing) |
(missing) |
| Landscape overlap matrix (required): |
Patent/Family Member (AU) |
Grant/Status |
Claimed Subject Matter |
Overlap with AU2010212371 |
Blocking/Beating Risk |
Key Takeaways
- AU2010212371 can be analyzed for scope and landscape only using the published claim set and specification plus family/prosecution status.
- The input provides only the application number, not the document text or family data, so a complete and accurate claim-by-claim scope and infringement landscape cannot be produced.
FAQs
-
What determines the enforceable scope of an Australian drug patent application like AU2010212371?
The verbatim independent claim language, claim dependencies, and definitions in the specification.
-
Can AU2010212371’s claim scope be derived from the application number alone?
No; scope analysis requires the published claims/specification text and grant status.
-
What is the biggest driver of infringement risk for drug patents in Australia?
Boundaries in the claims for the active ingredient identity, formulation/dose parameters, and the method/use steps.
-
How do family members affect Australia freedom-to-operate?
Overlapping or sequential claims in related jurisdictions often map to the same active and can indicate where narrower Australian claim fallbacks may exist.
-
What makes landscape conclusions materially different from a basic list of patents?
Claim construction, priority dates, and the actual overlap set with granted or pending Australian claims.
References
[1] Australian Patent Office. AU2010212371 (publication record). Australian IP Australia database.
[2] World Intellectual Property Organization. Patent documents and publication metadata for AU2010212371 (as indexed in global patent databases).
